# Shortness Of Breath Questionnaire Validation Study

> **NCT00411372** · PHASE3 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg

## Key facts

- **NCT ID:** NCT00411372
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects enrolled. Study was canceled before active
- **Last updated:** 2015-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411372, "Shortness Of Breath Questionnaire Validation Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00411372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*